<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Article Tag Suite 1.1//EN"
  "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         article-type="research-article"
         xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>American Journal of PharmTech Research</journal-title>
        <abbrev-journal-title abbrev-type="publisher">AJPTR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2249-3387</issn>
      <publisher>
        <publisher-name>undefined</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">AJPTR52006</article-id>
      <title-group>
        <article-title>The Degradations Routes of Ramipril and Its Products</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Aschar</surname>
            <given-names>Guilherme Davi</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Oliveira</surname>
            <given-names>Laura</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rosa</surname>
            <given-names>Paulo Cesar Pires</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" iso-8601-date="2015-04-01">
        <month>04</month>
        <day>01</day>
        <year>2015</year>
      </pub-date>
      <volume>5</volume>
      <issue>2</issue>
      <abstract>
        <p>Ramipril is a prodrug of the active metabolite ramiprilat, it inhibits angiotensin-converting enzyme and consequent raise in blood pressure. Its pharmacologic effect aids the treatment of hypertension, congestive heart failure and reduces mortality in post myocardial infarction patients. As for other drugs, Ramipril might degrade upon storage and compromise the quality, efficacy and safety of the product. In order to avoid deterioration, it is important to characterize the degradation products and source of stress (temperature, water content, oxidizers, etc). This review aims to summarize the data concerning the subject and serve as a guide for further studies.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Ramipril</kwd>
        <kwd>Impurities</kwd>
        <kwd>Stress testing</kwd>
        <kwd>Degradation Pathways</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <!-- Full article body not available in metadata-only JATS export. See PDF/HTML galley. -->
  </body>
  <back/>
</article>
